Virbac Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Virbac yıllık ortalama 1.3% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar declining at 5.7% annual. Gelirler growing yılda ortalama 8.7% oranında artmaktadır. Virbac'in özkaynak karlılığı 13.4% ve net marjı 10.3%'dir.
Anahtar bilgiler
1.31%
Kazanç büyüme oranı
1.52%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 16.27% |
| Gelir büyüme oranı | 8.70% |
| Özkaynak getirisi | 13.37% |
| Net Marj | 10.30% |
| Sonraki Kazanç Güncellemesi | 17 Sep 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 07
VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing
Analysts have maintained their price target for Virbac at €412.88, citing unchanged assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Virbac has scheduled a Special and Extraordinary Shareholders Meeting for June 29, 2026.Anlatı Güncellemesi • May 24
VIRP: Stable Margins And P/E Assumptions Will Support Future Upside Repricing
Analysts have made a very small adjustment to Virbac's fair value estimate, nudging the price target from €413.00 to around €412.88. This reflects updated fine tuning of revenue growth, profit margin and future P/E assumptions.Anlatı Güncellemesi • May 09
VIRP: Human Animal Bond Partnership Will Support Future Upside Repricing
Analysts have made a small upward adjustment to their Virbac target, lifting fair value from about €412.33 to €413.00. This reflects updated assumptions around the discount rate, revenue growth, profit margin and future P/E.Anlatı Güncellemesi • Mar 11
VIRP: Human Animal Bond Partnership Will Support 2026 Outlook Repricing
Analysts have made a small adjustment to their Virbac price target to reflect marginal tweaks in fair value, growth and margin assumptions, trimming it by about €0.50 to €412.33. What's in the News Virbac entered a new partnership with the Human Animal Bond Research Institute to support efforts that strengthen the human animal bond and its impact on companion animal and human health, focusing on science, education and collaboration (Key Developments).Anlatı Güncellemesi • Feb 25
VIRP: Stable Assumptions And 2026 Guidance Will Support Bullish Repricing
Analysts have maintained their Virbac price target at €412.82, indicating unchanged views on fair value, discount rate, growth assumptions, and margin expectations for the company. What's in the News Virbac entered a partnership with the Human Animal Bond Research Institute (HABRI) to support efforts that strengthen the human animal bond and its impact on companion animal and human health, with a focus on science, education and collaboration (Key Developments).Anlatı Güncellemesi • Feb 11
VIRP: Stable Inputs And 2026 Guidance Will Support Bullish Repricing
Analysts have kept Virbac's fair value estimate steady at €412.82 per share, with only small technical adjustments to inputs such as the discount rate and assumed future P/E informing this unchanged price target. What's in the News Virbac issued earnings guidance for 2026, including the impact of the Thyronorm acquisition, with revenue growth expected to be between 5.5% and 7.5% at constant rates and scope (Key Developments).Anlatı Güncellemesi • Jan 26
VIRP: Broad Regional Execution And 2026 Outlook Will Support Bullish Repricing
Narrative Update The analyst price target for Virbac has been raised from €390 to €415, with analysts citing accelerated growth across all regions as the key driver of this change. Analyst Commentary Analysts lifting their price target on Virbac to €415 from €390 are focusing on how the company is executing its growth plans across regions and what that could mean for valuation and risk.Anlatı Güncellemesi • Jan 07
VIRP: Broad Regional Acceleration Will Support Upgraded Buy Rating Into 2025
Narrative Update on Virbac Analysts have increased their price target on Virbac to €415 from €390, citing what they describe as accelerated growth across all regions as the key driver for their updated view. Analyst Commentary Recent research points to a more constructive stance on Virbac, with analysts raising their price target to €415 from €390 as they reassess the company’s growth profile.Anlatı Güncellemesi • Dec 23
VIRP: Broad Regional Acceleration Will Sustain Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac from EUR 390 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to a higher price target as a reflection of stronger than expected execution in scaling operations across all regions.Anlatı Güncellemesi • Dec 09
VIRP: Broad Regional Momentum Will Support Upgraded Buy Rating Through 2025
Analysts have raised their price target on Virbac by EUR 25 to EUR 415, citing an acceleration in the company’s growth across all regions. Analyst Commentary Following the recent upgrade, research coverage has focused on the sustainability of Virbac’s growth acceleration and its implications for valuation.Anlatı Güncellemesi • Nov 25
VIRP: Accelerated Regional Momentum Will Sustain an Upgraded Bullish Outlook for 2025
Analysts have raised Virbac's price target from €390 to €415, citing accelerated growth across all regions as the key driver for their more positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts cite a clear acceleration in Virbac's growth across all geographic regions, which supports a more positive outlook for the company.Anlatı Güncellemesi • Nov 07
VIRP: Accelerated Regional Expansion Will Drive Upgraded Earnings Outlook Next Year
Narrative Update on Virbac Analysts have raised Virbac's price target from €398 to €403, citing accelerated growth across all regions as the primary driver for this upward revision. Analyst Commentary The most recent research notes reflect increased optimism around Virbac's trajectory, with upward revisions to both rating and price targets.Analiz Makalesi • Oct 05
Is There An Opportunity With Virbac SA's (EPA:VIRP) 43% Undervaluation?
Key Insights Virbac's estimated fair value is €563 based on 2 Stage Free Cash Flow to Equity Virbac's €323 share price...Analiz Makalesi • Sep 17
Analysts Have Made A Financial Statement On Virbac SA's (EPA:VIRP) First-Quarter Report
Shareholders might have noticed that Virbac SA ( EPA:VIRP ) filed its quarterly result this time last week. The early...Analiz Makalesi • Aug 30
There's Reason For Concern Over Virbac SA's (EPA:VIRP) Price
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 19.3x might make it look like a sell right now compared...Analiz Makalesi • Jun 23
Is There An Opportunity With Virbac SA's (EPA:VIRP) 46% Undervaluation?
Key Insights Virbac's estimated fair value is €601 based on 2 Stage Free Cash Flow to Equity Virbac's €324 share price...Analiz Makalesi • May 18
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 15x, you may consider...Analiz Makalesi • Apr 30
Virbac (EPA:VIRP) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Yeni Anlatı • Mar 16
Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals
Strategic R&D investments and facility expansions aim to drive innovation, operational efficiency, and future revenue growth, potentially enhancing profitability.Analiz Makalesi • Jan 24
Earnings Not Telling The Story For Virbac SA (EPA:VIRP)
Virbac SA's ( EPA:VIRP ) price-to-earnings (or "P/E") ratio of 17.9x might make it look like a sell right now compared...Analiz Makalesi • Oct 06
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued
Key Insights The projected fair value for Virbac is €699 based on 2 Stage Free Cash Flow to Equity Virbac is estimated...Analiz Makalesi • Sep 18
Virbac SA Just Beat Revenue Estimates By 6.0%
It's been a good week for Virbac SA ( EPA:VIRP ) shareholders, because the company has just released its latest...Analiz Makalesi • Aug 31
Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares
With a price-to-earnings (or "P/E") ratio of 24x Virbac SA ( EPA:VIRP ) may be sending very bearish signals at the...Analiz Makalesi • Jun 15
Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All
Key Insights Virbac's Annual General Meeting to take place on 21st of June Salary of €379.0k is part of CEO Sebastien...Analiz Makalesi • Jun 10
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Virbac fair value estimate is €551 Virbac's €363 share price...Analiz Makalesi • May 21
Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected
With a price-to-earnings (or "P/E") ratio of 24.2x Virbac SA ( EPA:VIRP ) may be sending bearish signals at the moment...Analiz Makalesi • Mar 22
Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results
Last week saw the newest yearly earnings release from Virbac SA ( EPA:VIRP ), an important milestone in the company's...Analiz Makalesi • Jan 18
Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?
Key Insights The projected fair value for Virbac is €440 based on 2 Stage Free Cash Flow to Equity Virbac's €340 share...Analiz Makalesi • Dec 27
Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up
Virbac SA ( EPA:VIRP ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking...Analiz Makalesi • Oct 19
Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Sep 26
Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Key Insights Virbac's estimated fair value is €411 based on 2 Stage Free Cash Flow to Equity Current share price of...Analiz Makalesi • Sep 05
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analiz Makalesi • Jun 20
A Look At The Fair Value Of Virbac SA (EPA:VIRP)
Key Insights The projected fair value for Virbac is €337 based on 2 Stage Free Cash Flow to Equity Current share price...Analiz Makalesi • May 31
Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analiz Makalesi • Apr 09
Is Virbac (EPA:VIRP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Feb 28
Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?
Key Insights The projected fair value for Virbac is €437 based on 2 Stage Free Cash Flow to Equity Virbac's €288 share...Analiz Makalesi • Nov 25
Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...Analiz Makalesi • Oct 14
Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analiz Makalesi • Aug 07
An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Virbac SA ( EPA:VIRP...Analiz Makalesi • Jun 26
These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • May 01
Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Analiz Makalesi • Mar 26
We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Jan 26
Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate
How far off is Virbac SA ( EPA:VIRP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Analiz Makalesi • Dec 28
Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Virbac nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 25 | 1,465 | 151 | 680 | 0 |
| 30 Sep 25 | 1,449 | 142 | 678 | 0 |
| 30 Jun 25 | 1,433 | 133 | 675 | 0 |
| 31 Mar 25 | 1,415 | 139 | 660 | 0 |
| 31 Dec 24 | 1,397 | 145 | 645 | 0 |
| 30 Sep 24 | 1,368 | 143 | 625 | 0 |
| 30 Jun 24 | 1,339 | 141 | 605 | 0 |
| 31 Mar 24 | 1,293 | 131 | 589 | 0 |
| 31 Dec 23 | 1,247 | 121 | 573 | 0 |
| 30 Sep 23 | 1,229 | 120 | 570 | 0 |
| 30 Jun 23 | 1,210 | 119 | 568 | 0 |
| 31 Mar 23 | 1,213 | 121 | 563 | 0 |
| 31 Dec 22 | 1,216 | 122 | 557 | 0 |
| 30 Sep 22 | 1,184 | 120 | 535 | 0 |
| 30 Jun 22 | 1,151 | 119 | 513 | 0 |
| 31 Mar 22 | 1,107 | 116 | 500 | 0 |
| 31 Dec 21 | 1,064 | 113 | 487 | 0 |
| 30 Sep 21 | 1,025 | 137 | 473 | 0 |
| 30 Jun 21 | 985 | 161 | 459 | 0 |
| 31 Mar 21 | 960 | 148 | 449 | 0 |
| 31 Dec 20 | 934 | 136 | 439 | 0 |
| 30 Sep 20 | 944 | 104 | 444 | 0 |
| 30 Jun 20 | 953 | 72 | 448 | 0 |
| 31 Mar 20 | 946 | 62 | 451 | 0 |
| 31 Dec 19 | 938 | 52 | 454 | 0 |
| 30 Sep 19 | 921 | 43 | 449 | 0 |
| 30 Jun 19 | 903 | 34 | 445 | 0 |
| 31 Mar 19 | 886 | 27 | 446 | 0 |
| 31 Dec 18 | 869 | 20 | 446 | 0 |
| 30 Sep 18 | 862 | 8 | 442 | 0 |
| 30 Jun 18 | 854 | -4 | 438 | 0 |
| 31 Mar 18 | 858 | -3 | 440 | 0 |
| 31 Dec 17 | 862 | -3 | 442 | 0 |
| 30 Sep 17 | 871 | 16 | 444 | 0 |
| 30 Jun 17 | 879 | 35 | 446 | 0 |
| 31 Mar 17 | 876 | 35 | 449 | 0 |
| 31 Dec 16 | 872 | 35 | 452 | 0 |
| 30 Sep 16 | 861 | 30 | 459 | 0 |
| 30 Jun 16 | 850 | 26 | 466 | 0 |
| 31 Mar 16 | 851 | 18 | 463 | 0 |
| 31 Dec 15 | 853 | 9 | 460 | 0 |
| 30 Sep 15 | 846 | 21 | 441 | 0 |
Kaliteli Kazançlar: VIRP yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: VIRP 'nin mevcut net kar marjları (10.3%) geçen yılın (10.4%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: VIRP şirketinin kazancı son 5 yılda yılda 1.3% oranında arttı.
Büyüme Hızlandırma: VIRP 'un son bir yıldaki kazanç büyümesi ( 3.9% ) 5 yıllık ortalamasını (yıllık 1.3% ) aşıyor.
Kazançlar vs. Sektör: VIRP geçen yılki kazanç büyümesi ( 3.9% ) Pharmaceuticals sektörünün 3.9% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: VIRP 'nin Özsermaye Getirisi ( 13.4% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/12 16:41 |
| Gün Sonu Hisse Fiyatı | 2026/07/10 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Virbac SA 12 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Delphine Le Louet | Bernstein |
| Laurent Gelebart | BNP Paribas |
| Arnaud Cadart | CIC Market Solutions (ESN) |